These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 3923849

  • 21. [Epidemiologic study of measles, rubella and mumps with regard to the possibility of their control by immunization].
    Rodríguez Borrego MJ, García León J, Bolumar F, Nájera E.
    Rev Sanid Hig Publica (Madr); 1985; 59(1-2):117-25. PubMed ID: 4059834
    [No Abstract] [Full Text] [Related]

  • 22. Measles-mumps-rubella immunization of susceptible hospital employees during a community measles outbreak: cost-effectiveness and protective efficacy.
    Stover BH, Adams G, Kuebler CA, Cost KM, Rabalais GP.
    Infect Control Hosp Epidemiol; 1994 Jan; 15(1):18-21. PubMed ID: 8133004
    [Abstract] [Full Text] [Related]

  • 23. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K, Nicoara C, Germann D, Matter L.
    Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837
    [Abstract] [Full Text] [Related]

  • 24. Measles-mumps-rubella vaccine. Advance in immunization.
    Barkin SZ, Barkin RM.
    Rocky Mt Med J; 1975 Jun 25; 72(6):247-50. PubMed ID: 1145029
    [No Abstract] [Full Text] [Related]

  • 25. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Jun 14; 62(RR-04):1-34. PubMed ID: 23760231
    [Abstract] [Full Text] [Related]

  • 26. MMR vaccine--one year on.
    Walker D.
    Practitioner; 1990 May 22; 234(1489):550-2. PubMed ID: 2392406
    [No Abstract] [Full Text] [Related]

  • 27. Measles and mumps immunization: benefit versus risk factors.
    Krugman S.
    Dev Biol Stand; 1979 May 22; 43():253-7. PubMed ID: 520672
    [Abstract] [Full Text] [Related]

  • 28. A benefit-cost analysis of mumps vaccine.
    Koplan JP, Preblud SR.
    Am J Dis Child; 1982 Apr 22; 136(4):362-4. PubMed ID: 6803581
    [Abstract] [Full Text] [Related]

  • 29. Vaccination with a combined vaccine against measles, mumps and rubella aiming at elimination of the three diseases.
    Böttiger M, Christenson B, Strandell A, Romanus V.
    Dev Biol Stand; 1986 Apr 22; 65():37-43. PubMed ID: 3556776
    [Abstract] [Full Text] [Related]

  • 30. The measles-mumps-rubella vaccination program in Finland.
    Redd SC, Wharton M, Hadler SC, Orenstein WA.
    N Engl J Med; 1995 Apr 20; 332(16):1102-3. PubMed ID: 7898540
    [No Abstract] [Full Text] [Related]

  • 31. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM, Baker L, Starr SE, Levine BL, Books E, Plotkin SA.
    Pediatrics; 1986 Oct 20; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [Abstract] [Full Text] [Related]

  • 32. ACIP issues recommendations to eliminate measles, rubella and congenital rubella syndrome and to control mumps.
    Rose VL.
    Am Fam Physician; 1998 Nov 01; 58(7):1682, 1685-6. PubMed ID: 9824963
    [No Abstract] [Full Text] [Related]

  • 33. The measles-mumps-rubella vaccination program in Finland.
    Lerman SJ.
    N Engl J Med; 1995 Apr 20; 332(16):1103. PubMed ID: 7898541
    [No Abstract] [Full Text] [Related]

  • 34. Measles, mumps, and rubella vaccine coverage in 2 year old children in East Lancashire--better than it looks.
    Clark A, Marshall R.
    Commun Dis Public Health; 1999 Jan 20; 2(1):50-3. PubMed ID: 10462897
    [Abstract] [Full Text] [Related]

  • 35. Measles, mumps, and rubella: monitoring in Switzerland through a sentinel network, 1986-94. Sentinella Arbeitsgemeinschaft.
    Matter HC, Cloetta J, Zimmermann H.
    J Epidemiol Community Health; 1995 Aug 20; 49 Suppl 1(Suppl 1):4-8. PubMed ID: 7561669
    [Abstract] [Full Text] [Related]

  • 36. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.
    Böttiger M, Christenson B, Romanus V, Taranger J, Strandell A.
    Br Med J (Clin Res Ed); 1987 Nov 14; 295(6608):1264-7. PubMed ID: 3120971
    [Abstract] [Full Text] [Related]

  • 37. Antibody response following measles-mumps-rubella vaccine under conditions of customary use.
    Brunell PA, Weigle K, Murphy MD, Shehab Z, Cobb E.
    JAMA; 1983 Sep 16; 250(11):1409-12. PubMed ID: 6887461
    [Abstract] [Full Text] [Related]

  • 38. Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland.
    Paunio M, Virtanen M, Peltola H, Cantell K, Paunio P, Valle M, Karanko V, Heinonen OP.
    Am J Epidemiol; 1991 Jun 01; 133(11):1152-60. PubMed ID: 2035518
    [Abstract] [Full Text] [Related]

  • 39. Targeted mailing of information to improve uptake of measles, mumps, and rubella vaccine: a randomised controlled trial.
    Mason BW, Donnelly PD.
    Commun Dis Public Health; 2000 Mar 01; 3(1):67-8. PubMed ID: 10743326
    [Abstract] [Full Text] [Related]

  • 40. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ, Robertson PW, Whybin LR.
    Med J Aust; 1994 Apr 18; 160(8):478-82. PubMed ID: 8170422
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.